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Equine herpesvirus 1 (EHV-1) causes respiratory disease, abortion
and neurological disorders in the horse (Allen and Bryans, 1986). In
recent years, there have been increasing reports of EHV-1-related
neurological disorders (Equine herpesvirus myeloencephalopathy,
EHM) in the horse in Europe and the United States (Borchers et al.,
2006). The neurological symptoms occur in various degrees frommild
ataxia to paraplegia. The neurological signs may be caused by
vasculitis followed by hemorrhage, thrombosis, hypoxia and second-
ary ischemic degeneration (Jackson et al., 1977; Kohn and Fenner,
1987).Characterization of neuropathogenic EHV-1 has begun in recent
years at the molecular level. Allen et al. (1983) described 16
electropherotypes, which showed signiﬁcant differences in DNA
ﬁngerprints of EHV-1. The main electropherotypes are P and B, both of
which are found in the horse population in Japan (Kirisawa et al., 1993;
Matsumura et al., 1992). EHV-1s which were isolated from horses with
neurological disorders have been typed EHV-1 P only. EHM caused by
EHV-1Bhas never been reported so far. Therefore EHV-1B seems to lose
neuropathogenicity in the horse.We previously found that EHV-1 P and
B in Japanmainly differed in ORF64,which encodes the immediate early
(IE) or the infected cell protein 4 (ICP4) (Pagamjav et al., 2005).We also
found that ORF64 of EHV-1 Bmight be caused by natural recombination
between EHV-1 P and EHV-4, another equine pathogen with mild
respiratory pathogenicity. Therefore we suggested that ICP4 is possibly
involved in the neuropathogenicity of EHV-1. Recent studies have
identiﬁed a single nucleotide polymorphism (SNP) signiﬁcantly
associated with EHM (Nugent et al., 2006). The SNP is a substitution
of adenine (A) by guanine (G), at the nucleotide (nt) 2254 of the EHV-1
gene (ORF30) encoding the viral DNA polymerase and the consequent
substitutionof asparagine (N)byaspartic acid (D) at aminoacidposition
752. This hypothesis was supported by later studies based on
experimental infection with various ﬁeld isolates and molecular
recombinants (Leutenegger et al., 2008; Yamada et al., 2008; Vissani
et al., 2009; Smith et al., 2010). Matsumura et al. (1998) reported that
the glycoprotein I (gI, ORF73) and glycoprotein E (gE, ORF74) were
260 S. Kasem et al. / Virology 400 (2010) 259–270associated with virulence of EHV-1. Thus, multiple genes might be
associated with the occurrence of EHM.
The genes of herpesvirus are classiﬁed as essential or nonessential
for growth in cultured cells; for example, ICP4 and ORF30 are essential
genes of EHV-1, while gI and gE are nonessential. Analysis of essential
genes is difﬁcult and time consuming with traditional methods that
use the homologous recombination in eukaryotic cells which consti-
tutively express the target essential gene product. An alternative
approach using bacterial artiﬁcial chromosome (BAC) has recently
become the preferred method (Brune et al., 2000). This approach
allows rapid and efﬁcient alteration of herpes viral genome in
Escherichia coli. In principle, any essential and non-essential genes
onBAC canbemodiﬁed for deletion, alternation, and replacementwith
other genes. By establishing a BAC system, researchers can easily
perform recombination of any genes including essential and nones-
sential genes using genetics of E. coli (Smith et al., 2005).
Until today, herpesvirus genomes have been cloned as BAC including
pseudorabies virus (Smith and Enquist, 2000), human cytomegalovirus
(Yu et al., 2002), herpes simplex virus type 1 (Tanaka et al., 2003),
varicella zoster virus (Brune et al., 2000), Epstein–Barr virus (Kanda et
al., 2004), rhesus cytomegarovirus (Chang and Barry, 2003) and EHV-1
(Goodman et al., 2007; Hansen et al., 2006; Rudolph et al., 2002).
Osterrieder and his colleagues have cloned the EHV-1 genome using the
KyA, RacL11 and Ab4p strains (Goodman et al., 2007; Rudolph et al.,
2002) and Hansen et al. (2006) used the HVS25A strain as sources of
BAC. KyA, RacL11 and Ab4p BAC were constructed by insertion of BAC
vector sequences into the ORF71 (gp2 gene) in the viral genome.
Although the ORF71 is a nonessential gene, its product, gp2, seems to
contribute in EHV-1 virulence and pathogenesis (Smith et al., 2005).
Therefore, BAC sequences need to be reverted to the original sequences
to use these BACs prior to pathogenicity evaluation (Goodman et al.,
2007). The HVS25A strain BAC, which had a BAC vector inserted to the
intergenic region betweenORF62 andORF63, appeared to have a similar
growth towild-type in cell culture (Hansen et al., 2006). HVS25A strain
was isolated from an aborted foal (Whalley et al., 1981) and used in a
murine model of respiratory disease (Csellner et al., 1998). However,
there is no data about the neuropathogenicity on HVS25A strain. The
Ab4p strain is a neurovirulent strain that was isolated from a case
of equine paresis (Gibson et al., 1992). Adding with a whole genome
sequence (Telford et al., 1992), Ab4p has been conﬁrmed to cause
neurological disorders in experimental infection of mice, hamsters
and horses (Awan et al., 1990; Fukushi, et al., 2000; Gibson et al.,
1992). Therefore Ab4p appears to be the suitable strain for analysis of
neuropathogenicity of EHV-1.
EHV-1 UL24 is encoded by ORF37. UL24 homologs are present
throughout the Herpesviridae family. The HSV-1 UL24 is a 30-kDa
nuclear-associated protein that is not required for growth in cultured
cells (Pearson and Coen, 2002). The UL24 homolog identiﬁed in
bovine herpes virus type 1 (BHV-1) was shown to have a transcription
proﬁle similar to that of HSV-1 UL24. Deletion of the BHV-1 UL24 open
reading frame (ORF) had little effect on viral replication in vitro
(Whitbeck et al., 1994). Although the molecular function of UL24
protein is not known, mutation of the HSV-1 gene results in the
development of a syncytial plaque-forming phenotype following
infection of certain cell types in vitro. Studies using HSV-1 UL24 point
mutants in a murine ocular disease model suggested that the HSV-1
UL24 gene product was important for peripheral replication in corneal
tissue, acute replication in sensory ganglia, and reactivation from
explanted mouse ganglia. The UL24 of HSV-2 is reported as a
pathogenicity determinant in murine and guinea pig disease models
(Blakeney et al., 2005). Inoculating three different types of cell lines
with UL24 mutant HSV-2, they reported that it had no effect on viral
replication or virus titers as it yielded a cytopathic effect with
syncytial formation and virus titers as those produced by the wild-
type virus. However, the function of EHV-1 UL24 has not been
resolved yet.In this study, we describe the construction of an infectious BAC of
neuropathogenic EHV-1 based on the Ab4p strain (Ab4p BAC). In Ab4p
BAC, a BAC vector is inserted into the intergenic region between ORF2
and ORF3. Insertion of a BAC vector into EHV-1 genome was examined
by using lambda site-speciﬁc recombination technique (Groth and
Calos, 2004; Nash, 1990; Nash and Robertson, 1981; Patsey and Bruist,
1995). The BAC sequence could be efﬁciently removed from the viral
genome by using a lambda recombination system, resulting in Ab4p
strain without BAC sequence (Ab4p attB). The Ab4p attB showed
neurological symptoms inmice and its growth kinetics in cultured cells
was the same as that of the wild-type Ab4p. This Ab4p BAC and Ab4p
attB will be signiﬁcant tools for the analyzing the neuropathogenesis
of EHV-1. Using this Ab4p BAC, an ORF37 deletion mutation and the
corresponding revertant virus were constructed to characterize the
ability of the virus to replicate in different cell lines in vitro and cause a
disease after intranasal inoculation in the CBA/N1 mice model. Our
results suggested that the ORF37 has a role in neuropathogenicity of
EHV-1 in the mouse model.
Results
Construction of Ab4p BAC and Ab4p attB
Wehave cloned the full-length EHV-1 Ab4p genome in pZC320-GFP,
the modiﬁed pZC320 vector, as pAb4p BAC (Fig. 1). We conﬁrmed that
pAb4p BAC was maintained in E. coli. Ab4p attB was generated by
excising the pZC320-GFP sequence from pAb4p BAC by LR clonase
reaction and subsequent transfection in RK-13 cells. The NotI digestion
sites of the insertion region of pZC320-GFP are shown in Fig. 2A. The
digestion of Ab4p BAC genome caused unique 1.4, 5.0 and 5.9 kbp
fragments due to the pZC320-GFP insertion (Fig. 2B, lanes 1 and 2). On
the other hand, Ab4p and Ab4p attB genomehad a 3.1 kbp fragment but
not 1.4, 5.0 and 5.9 kb fragments (Fig. 2B lanes 3 and 4). For Ab4p
BAC, insertion of pZC320-GFP was conﬁrmed by hybridization to the
1.4 kb fragmentwith GFP probe (Fig. 2C a, lanes 1 and 2) and the 5.0 kb
fragment with ORF3 probe (Fig. 2C b, lanes 1 and 2). For Ab4p attB,
excision of pZC320-GFP was conﬁrmed by hybridization to the 3.1 kb
fragment with ORF3 probe (Fig. 2C b, lane 3) and no bands with GFP
probe (Fig. 2C a, lane 3) as well as Ab4p (Fig. 2C a and b, lane 4).
In vitro growth kinetics and properties of Ab4p BAC and Ab4p attB
Growth properties including the multi-step growth curves and
plaque sizes in MDBK cells were compared among Ab4p BAC, Ab4p
attB and Ab4p. In multi-step growth kinetics, the growth patterns and
ﬁnal growth titers of Ab4p BAC and Ab4p attB were similar to that of
wild-type Ab4p (Fig. 3A). Plaque morphology and average plaque size
of Ab4p attB and Ab4p BAC were identical to that of Ab4p (Fig. 3B).
There was no signiﬁcant difference in plaque size among the viruses
(pb0.01). Therefore, the growth properties of Ab4p BAC and Ab4p
attB were concluded to be similar to that of wild-type Ab4p.
Pathogenicity of the Ab4p BAC and Ab4p attB in animal models
The pathogenicity of the Ab4p BAC, Ab4p attB and wild-type Ab4p
were evaluated in the mouse model. CBA/N1 mice were inoculated
with the viruses intranasally. The body weight and clinical signs were
monitored every day for two weeks. The body weight change of Ab4p
attB was similar to that of Ab4p. On the other hand, the body weight
change of Ab4p BAC was the same as that of control mice. The mice,
which were inoculated Ab4p or Ab4p attB virus, showed the same
clinical symptoms, such as hyperactivity, paralysis, arching of the back
and lethargy. On the other hand, Ab4p BAC showed hyperactivity only
after 7 days post inoculation (data not shown).
This result suggested that Ab4p attB maintained the pathogenicity
of the wild-type Ab4p but Ab4p BAC lost its pathogenicity in the
Fig. 1. Schematic diagrams of construction of Ab4p BAC and Ab4p attB. A pZC320-GFP-Ab4p (C) was constructed by BP clonase reaction between attB site in the pUC19-Ab4p-attB (A)
and attP site in the pZC320-GFP-attP (B). Ab4p BAC virus (E) was constructed by homologous recombination in RK-13 cells (D). RK-13 cells were infected Ab4p and transfected with
pZC320-GFP-Ab4p. Then, plaques containing the BAC virus were examined in MDBK cells by using GFP ﬂuorescence as a marker. The desired virus plaque was identiﬁed andmarked
under ﬂuorescent microscopy in order to pick up the plaque clone for further serial plaque puriﬁcation. Ab4p BAC maintained in E. coli DH10β, which was generated by
electroporation of circular viral DNA of Ab4p BAC. Ab4p attB DNA, which excised BAC sequence from Ab4p BAC DNA, was generated by LR clonase reaction (F). RK-13 cells were
transfected with Ab4p attB DNA. Then, the purity of the plaques was examined in MDBK cells. The desired virus, which did not show ﬂuorescence, was identiﬁed and marked under
ﬂuorescent microscopy for further cloning procedure.
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be excised prior to pathogenicity evaluation of each virus gene of
EHV-1 in the mouse model.
Deletion and characterization of ORF37 in EHV-1
The roles and signiﬁcance of ORF37 of EHV-1 were investigated
by using molecular recombination of Ab4p BAC. To construct an
ORF37 deletion mutant, the ORF37 of pAb4p BAC was replaced with aprokaryotic selection marker, the rpsL-neo gene conferring strepto-
mycin sensitivity and kanamycin resistance, by Red mutagenesis in
E. coli. The resulting ORF37 negative Ab4p BAC mutant was termed
pAb4pΔORF37 BAC (Figs. 4A and B).
The correct insertion of the rpsL-neo gene anddeletion of ORF37was
conﬁrmed by PCR and nucleotide sequencing. pAb4pΔORF37 BAC DNA,
isolated from E. coli, was treated with LR clonase enzyme to excise the
pZC320-GFP fragment and transfected into RK-13 cells to reconstitute
the virus with ORF37-deletion, designated Ab4pΔORF37. To restore
Fig. 2. Conﬁrmation of Ab4p BAC and Ab4p attB by restriction digestion and Southern blotting. A: Location of the NotI digestion site in Ab4p BAC, Ab4p attB and Ab4p. B: NotI
digestion of Ab4p BAC genome DNA in E. coli and virus (lanes 1 and 2), Ab4p attB (lane 3) and Ab4p genomes (lane 4). Ab4p BAC had fragments of about 5.9, 1.4 and 5.0 kbp
containing BAC vector sequence. Ab4p attB and Ab4p had an approximately 3.1 kbp fragment but not the 5.9, 1.4 and 5.0 kbp fragments. C: Genomic DNAs from Ab4p BAC, Ab4p attB
and Ab4p were digested with NotI and hybridized with probes speciﬁc for GFP (NotI/GFP probe, lanes 1 and 2) (a) or ORF3 (NotI/ORF3 probe, lanes 1, 2, 3 and 4) (b).
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and pAb4pΔORF37 BAC in DH10β resulted in replacement of rpsL-neo
gene with ORF37-encoding sequence and reconstitution of a revertant
BAC, pAb4pΔORF37R BAC. The ORF37 rescuant pAb4pΔORF37R BAC
DNA, isolated from E. coli, was reactedwith LR clonase to excise the BAC
fragment and transfected into RK13 cells to reconstitute the ORF37
rescuant virus, Ab4pΔORF37R.
The genotypes of all generated and tested viruses were conﬁrmed
by restriction enzyme analyses using HincII and PvuII, nucleotide
sequencing (data not shown), and PCR. When the ORF37 was present,
it resulted in a PCR product of 955 bp. The 955 bp product was
detected in cells infected with Ab4p, Ab4p attB and Ab4pΔORF37R
viruses (Fig. 4C, lanes 1, 2 and 4). Insertion of the rpsL gene instead of
ORF37 resulted in a product of 1420 bp in size in cells infected with
ORF37 deletion mutant Ab4pΔORF37 (Fig. 4C, lane 3).
In vitro growth properties of ORF 37-negative mutants in cultured
cell line
The in vitro growth properties of the generated ORF37-negative
virus were analyzed inMDBK cells. To assess a possible contribution of
ORF37 to the plaque formation of EHV-1, plaque areas of Ab4pΔORF37were quantiﬁed and compared to those of parental Ab4p, AB4p attB
and Ab4pΔORF37R. In three independent experiments, no signiﬁcant
difference was found in virus plaque sizes among wild-type, Ab4p
attB, Ab4pΔORF37, and Ab4pΔORF37R (data not shown). The results
indicate that the deletion of ORF37 in EHV-1 has no inﬂuence on
plaque size. The virus titers in MDBK cells inoculated with all tested
viruses were similar (Fig. 5). No differences were observed in the end-
point virus titers between Ab4pΔORF37 and parental Ab4p, Ab4p attB
and Ab4pΔORF37R.
Evaluation of growth activity by real-time RT-PCR
The growth activity of these viruses in MDBK cells was analyzed.
TheMDBK cells were infectedwith Ab4p, Ab4p attB, Ab4pΔORF37 and
Ab4pΔORF37R. The growth activities of all viruses were evaluated
through estimating ORF30 (DNA polymerase) RNA expression by real-
time RT-PCR with using β-actin gene expression as a control. β-actin
gene expression levels were the same among the MDBK cells infected
by all viruses. The expression of ORF30 of Ab4pΔORF37was nearly the
same as that of other viruses (data not shown). From these data, we
concluded that the ORF37 is completely dispensable for growth of
EHV-1 in cultured cells.
Fig. 3. Comparison of the in vitro growth properties of Ab4p, Ab4p BAC and Ab4p attB viruses. A:MDBK cells were infected with Ab4p, Ab4p BAC and Ab4p attB at anMOI of 0.1. At the
indicated times after infection, cells and supernatant were harvested separately as described in Materials and methods. Intracellular (a) and extracellular (b) viruses were titrated by
plaque formation on MDBK cells. The experiments were performed in triplicate. B: Relative plaque sizes of 50 randomly selected plaques of the Ab4p, Ab4p BAC and Ab4p attB. The
plaques formed by Ab4p, Ab4p BAC and Ab4p attB had identical plaque sizes (pb0.01) (A) and the same morphology (B). Error bars are standard errors.
Fig. 4. PCR analysis of the generated recombinant viruses using primers ORF37-1 and ORF37-2. Intact ORF37 yields a fragment of 955 bp, whereas virus DNA containing the rpsL gene
results in a fragment of 1420 bp. The molecular size marker is the 100-bp ladder (TOYOBO, Japan). PCR products from the different viruses were electrophoresed in 1% agarose gel.
Markers (lane M) were included to assess the sizes of the PCR products. Lane 1: Ab4p, lane 2: Ab4p attB, lane 3: Ab4pΔORF37, lane 4: Ab4pΔORF37R, M: Molecular weight marker.
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Fig. 5. Comparison of the in vitro growth curve of wild-type Ab4p and mutant viruses generated by BAC technology. MDBK Cells were infected at a MOI of 0.1. At the indicated times
after infection, cells and supernatant were harvested separately as described in Materials and methods. Intracellular (A) and extracellular (B) viruses were titrated by plaque
formation on MDBK cells. The experiments were performed in duplicate. Error bars are standard errors.
264 S. Kasem et al. / Virology 400 (2010) 259–270Effect of ORF37 deletion on transcription activities of ORFs 36, 38, 30 and 33
To evaluate the effects of the deletion of ORF37, transcript levels of
two neighboring ORFs (ORF36 and 38) and distant two ORFs (ORF30
and 33) were measured in MDBK cells infected with Ab4p, Ab4p attB,
Ab4pΔORF37 and Ab4pΔORF37R. β-actin levels in cells infected
with the different strains were the same. ORF37 transcripts were not
detected in cells infected with the deletion mutant, Ab4pΔORF37
(Fig. 6B). Deletion of ORF37 did not affect transcription levels ofFig. 6. Analysis of transcription activity of ORF36, ORF37 and ORF38 by real-time RT-
PCR. Real-time RT-PCR analysis was performed by using RNAs fromMDBK cells infected
with Ab4p, Ab4p-attB, Ab4pΔORF37 and revertant virus at different times 0, 2, 4, 6 and
8 h post infection. The ﬁgure compares the transcription levels of theses viral genes in
MDBK cells. Transcription activity of ORF36 (A), ORF37 (B) and ORF38 (C) were
examined by real-time RT-PCR. Relative quantity was evaluated by crossing point
method using with β-actin gene control.ORF36 (Fig. 6A), ORF30 and ORF33 (data not shown). Transcription
level of ORF38 in Ab4pΔORF37 infected cells was one log order lower
than that of other viruses until 4 h post infection and maintained the
same from 6 h and later post infection (Fig. 6C).
Experimental infection of mice
To evaluate the role of ORF37 in the neuropathogenicity of EHV-1,
CBA/N1 mice were inoculated with Ab4p, Ab4p attB, Ab4pΔORF37,
and Ab4pΔORF37R. Mice that were inoculated with Ab4p, Ab4p attB
and Ab4pΔORF37R showed nervous signs such as hyperactivity,
arching the back and paralysis (Table 1). These symptoms started
from 3-day post inoculation (dpi) in the Ab4p inoculated group and
by 4 and 5 dpi in the Ab4p attB and Ab4pΔORF37R inoculated groups.
Mice inoculated with Ab4pΔORF37 did not show any nervous signs
and gained body weight throughout the observation period (Fig. 7).
The body weights of mice inoculated with Ab4p, Ab4p attB and
Ab4pΔORF37R decreased from 5, 8 and 8 dpi, respectively. From 7 to
13 dpi, mean body weights of mice inoculated with Ab4pΔORF37
were signiﬁcantly larger than those of mice inoculated with Ab4p,
Ab4p-attB or Ab4pΔORF37R.
Viruses were consistently recovered from the lungs from 2 to 7 dpi
of mice inoculated with Ab4p, 2 to 6 dpi of mice inoculated with Ab4p
attB and from 3 to 7 dpi of mice inoculated with Ab4pΔORF37R,
respectively. On the other hand, the virus was recovered from 3 to
6 dpi in Ab4pΔORF37 inoculated mice. The viruses were recovered
from the brain of mice inoculatedwith Ab4p, Ab4p attB from 3 to 6 dpi
and Ab4pΔORF37 inoculatedmice from 4 to 7 dpi, while the virus was
recovered from Ab4pΔORF37 inoculated mice from 3 to 5 dpi with aTable 1
The nervous symptoms of mice inoculated with Ab4p, Ab4p-attB, Ab4pΔORF37 and
Ab4pΔORF37R.
Viruses Days post inoculation
0 1 2 3 4 5 6 7 8 9 10 11 12 13
Ab4p# − − − + + + + + +* +*
Ab4p attB − − − − + + + + + + + +* + +
Ab4p ΔORF37 − − − − − − − − − − − − − −
Ab4p ΔORF37R − − − − − + + + + + + + + +*
Mock − − − − − − − − − − − − − −
#: Mice inoculated with Ab4p were sacriﬁced on 10-day post inoculation humanely.
−: No nervous signs such as hyperactivity, paralysis, arching of the back and lethargy.
+: Nervous signs such as hyperactivity, paralysis, arching of the back and lethargy.
*: A mouse died.
Fig. 7.Mean bodyweight curves of mice inoculated with Ab4p andmutant viruses. Mice
in groups of four were infected intranasally with 1×105 pfu of the indicated virus. Mean
body weights were measured from 3 days before inoculation (−3 dpi) to 13 dpi. Each
data represents themean of the bodyweight for the indicated group. Error bars indicate
standard errors.
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the lungs of mice inoculated with Ab4p from 2 to 10 dpi, Ab4p attB
from 2 to 9 dpi, and Ab4pΔORF37R from 3 to 9 dpi. Virus DNA was
detected in the brain of mice inoculated with Ab4p from 3 to 10 dpi,
from 3 to 9 dpi in mice inoculated with Ab4p attB and from 4 to 8 dpi
in mice inoculated with Ab4pΔORF37R, while virus DNAwas detected
from 3 to 8 dpi in the lungs and from 3 to 7 dpi in the brain of mice
inoculated with Ab4pΔORF37 (Table 2).
None of the mice showed gross pathological changes at necropsy,
while the histopathological ﬁndings of the lungs showed interstitial
pneumonia in the lungs of all mice examined but not in mock
inoculated mice (data not shown). The brains of mice infected with
Ab4pΔORF37 did not show any histopathological changes or signs of
encephalitis nor meningitis, while the brains of mice infected with
wild-type Ab4p, Ab4p attB and Ab4pΔORF37R showed non-suppura-
tive encephalitis and meningitis (Fig. 8). The histopathological lesions
consisted of degeneration and necrosis of the neurons, lymphocytic
cell inﬁltration, perivascular cufﬁng, meningitis and gliosis (Table 3).In vitro growth properties of ORF 37-negative mutant in cultured mouse
neurons
The intracellular and extracellular virus titers of Ab4pΔORF37
were one order of magnitude lower than those of parental Ab4p, Ab4p
attB and Ab4pΔORF37R in mouse neuronal cells (Fig. 9), indicating
that the deletion of ORF37 affected EHV-1 multiplication in neuronal
cells.Table 2
Virus titration and DNA detection in mice organs inoculated with Ab4p, Ab4p attB, Ab4p Δ
Viruses Organs Day post inoculation
0 1 2 3 4
Ab4p Brain −/−* −/− −/− 2×102/+ 4×
Lung −/− −/− 5×102/+ 3×102/+ 2×
Ab4p attB Brain −/− −/− −/− 1×102/+ 5×
Lung −/− −/− 2×102/+ 1×102/+ 1×
Ab4p ΔORF37 Brain −/− −/− −/− −/+ −/
Lung −/− −/− −/− −/+ 3×
Ab4p ΔORF37R Brain −/− −/− −/− −/− 3×
Lung −/− −/− −/− 3×102/+ 2×
*: Virus titer in pfu per gram of organ/virus DNA detection.
+: Virus DNA was detected.
−: Virus titer was less than 1×102 pfu per gram or virus DNA was not detected.Discussion
We established an EHV-1 BAC clone, pAb4p BAC, based on the
neuropathogenic strain Ab4p. Our pAb4p BAC has no deletion of
genes, because the BAC vector (pZC320-GFP sequence) was inserted
into the intergenic region between ORF2 and ORF3 of Ab4p using the
lambda insertion–excision system. Thus, pAb4p BAC should maintain
the complete original genetic information of Ab4p.
The BAC vector (a 9.2 kb pZ320-GFP sequence) was inserted into
the intergenic region between ORF2 and ORF3 in pAb4p BAC. The
function of EHV-1 ORF2 is unknown. VZV ORF2, which is homologous
to the EHV-1 ORF3 gene, might not have a role in virus replication or
establishment of latency (Sato et al., 2002; Zhang et al., 2007). The
EHV-1 ORF3 product was suggested to play a role in the assembly of
the virus (Harty et al., 1993). Insertion of a large fragment, such as a
BAC vector, in virus genome might affect the virological character-
istics by inefﬁcient packaging (Smith and Enquist, 1999;Wagner et al.,
1999) or by interfering with the transcription of neighboring genes.
The present transcription analyses on ORF2, ORF3 and other viral
genes showed a decrease of transcripts in Ab4p BAC. The BAC vector
insertion might affect the transcription of genes on both side genes of
BAC insertion site and other genes. On the other hand, in Ab4p attB
infected cells, a decrease in the transcription was observed only
for ORF3. Ab4p attB behaved like the wild-type Ab4p in terms of in
vitro growth and neuropathogenicity in mouse, suggesting that low
transcriptions of ORF3 did not affect the viral growth in MDBK cells
and is not associated with the neuropathogenicity of EHV-1 in mouse.
Therefore Ab4p attB can be regarded as equivalent to the wild-type
Ab4p.
In this study, we constructed Ab4p BAC using BP and LR clonase.
This reaction is based on the lambda site-speciﬁc recombination
system, which is a reaction between attL and attR or attB and attP.
The clonase reactions are unidirectional, and are effective with both
insertions and deletions unlike the Cre/loxP system whose ability
to insert fragments is low (Thomson et al., 2003). We were able to
construct Ab4p BAC more efﬁciently than we could by normal
subcloning using restriction enzymes and ligase. Additionally, the
BAC vector in Ab4p BAC was ﬂanked by attL and attR. Therefore, the
BAC vector was easy to excise by the LR clonase reaction and to insert
by BP clonase.
CBA mouse showed brain lesions similar to those observed in
EHV-1 infected horses exhibiting neurological signs (Frampton et al.,
2004). Additionally, much is known about the genetic and the
biological characteristics of the CBA mice. Therefore, CBA mice seem
to be a good model for evaluating the neuropathogenicity of the Ab4p
BAC system. The pathogenicity of Ab4p attB was similar to that of the
wild-type Ab4p in mice. Especially, the same nervous symptoms were
observed in each mice inoculated with Ab4p and Ab4p attB, respec-
tively. These results suggest that Ab4p attB, which contains attB
sequence, can be used to evaluate the neuropathogenesis of EHV-1.ORF37 and Ab4p ΔORF37R.
5 6 7 8 9 10
103/+ 3×103/+ 4×102/+ −/+ −/+ −/+ −/+
104/+ 2×104/+ 1×103/+ 2×103/+ −/+ −/+ −/+
103/+ 2×102/+ 1×102/+ −/+ −/+ −/+ −/−
104/+ 1×103/+ 1×103/+ −/+ −/+ −/+ −/−
+ −/+ −/+ −/+ −/− −/− −/−
102/+ 2×103/+ 3×103/+ −/+ −/+ −/− −/−
102/+ 5×102/+ 2×103/+ 1×103/+ −/+ −/− −/−
102/+ 1×104/+ 3×102/+ 4×102/+ −/+ −/+ −/−
Fig. 8. Histological sections of brains of mice infected with wild-type, Ab4p attB, Ab4pΔORF37, Ab4pΔORF37R and mock. Mice were infected intranasally with the indicated doses.
Mice brains were stained with hematoxylin and eosin. Slides were inspected by light microscopy and photographed. A bar indicates 10 µm.
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sential for growth in cultured cells. However, when viral mutants
were tested in certain animal models, several of these genes proved to
be important in promoting viral replication and disease in vivo
(Subak-Sharpe and Dargan, 1998; Visalli and Brandt, 2002; Ward and
Roizman, 1994). We described the isolation of an ORF37 replacementmutant that is viable in vitro yet shows signiﬁcant attenuation in mice
models.
Analysis of the role of the ORF37 gene in the viral life cycle in vitro
and in vivo has been complicated by the fact that certain mutations in
ORF37 can affect the expression of the ORF38 (thyamidine kinase)
gene (Jacobson et al., 1989; Meignier et al., 1988; Sears et al., 1985).
Table 3
The pathological lesions of mice inoculated with Ab4p, Ab4p attB, Ab4p ΔORF37 and
Ab4p ΔORF37R.
Viruses Neuronal
degeneration
Meningitis Perivascular
cufﬁng
Glial
reaction
Interstitial
pneumonia
Ab4p +++ +++ +++ + +++
Ab4p attB +++ +++ ++ + ++
Ab4p ΔORF37 + − − − +
Ab4p ΔORF37R +++ ++ ++ − ++
−: No lesion; +: mild lesions; ++: moderate lesions; +++: severe lesions.
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the ORF37, had no obvious effect on expression or function of ORF38 or
ORF36, or on the transcription activities of ORF30 (DNA polymerase)
andORF33 (envelope glycoprotein B). Therefore phenomena observed
in this work could be regarded to be caused by the deletion of ORF37
itself.
Our results showed that the ORF37 protein is required for EHV-1 to
express neuropathogenicity in mouse, although the ORF37 product is
dispensable for viral replication in cell cultures. Also the results
showed that the virusmutant, Ab4pΔORF37, showed normalmultipli-
cation curves and the same plaque morphology in cell cultures as the
parental EHV-1 virus and other recombinant viruses used. On the
other hand, the ability of the EHV-1 ORF37 deletion mutant to repli-
cate in cultivated mouse neural cells derived from cerebral cortex
was signiﬁcantly impaired. The virus titers of Ab4pΔORF37 were one
order magnitude lower than those of parental Ab4p, Ab4p attB and
Ab4pΔORF37R. These results suggested that the ORF37 product
(UL24) plays a role in the multiplication of EHV-1 in neural cells by
unknown mechanism, although it is not needed in the ordinary cell
cultures such asMDBK, FEK and RK13 cells. Further studies are needed
to understand why ORF37 is needed for replication in mouse neural
cells but not in ordinary cells cultures.
The role of the ORF37 gene in vivo was assessed by intranasal
inoculation of parental and recombinant viruses into CBA/N1mice. Our
results showed the absence of neurological signs and the normal
body weight gain, with no mortalities in the mice inoculated with the
Ab4pΔORF37mutant. The histopathological ﬁndings showed no lesions
in the brain and mild lesions in the lungs of the mice inoculated with
Ab4pΔORF37 mutant. Moreover, Ab4pΔORF37 replication in the brain
and lungs was impaired as shown in Table 2, indicating that ORF37
protein is required for efﬁcient expression of EHV-1 pathogenesis in the
brain and lungs.
In summary, BAC cloning technology has opened new avenues for
the manipulation of several herpesvirus genomes. The feasibility of
mutagenesis of the EHV-1 BAC clone has been studied in this paper.Fig. 9. Growth curve of wild-type Ab4p and EHV-1 mutant viruses by using mouse neurons,
infection, cells and supernatant were harvested separately as described in Materials andmeth
MDBK cells. The experiments were performed in duplicate. Error bars are standard errors.Our ﬁndings reported here revealed no signiﬁcant difference between
wild-type EHV-1 and ORF37 negative mutant in their replication cycle
in cell culture. However, there is one order of magnitude decrease
in the mouse neuron cells inoculated with Ab4pΔORF37 than those
inoculated with Ab4p, Ab4p attB and Ab4pΔORF37R viruses. The
deletion of ORF37 did not affect on the transcription activities of the
neighboring genes and other genes. The mice inoculated with an
Ab4pΔORF37mutant did not show neurological symptoms, death and
body weight loss. Taken together, the ﬁndings at the present study
indicate that ORF37 of EHV-1 is one of the neuropathogenicity factors
of EHV-1.
Materials and methods
Virus and cells
EHV-1Ab4p strain (Gibson et al., 1992),whichwas kindly provided
by Dr. A. J. Davison, Glasgow University, Scotland, was used. The virus
was propagated in fetal equine kidney (FEK) cells. Other cells used in
this study were Madin–Darby bovine kidney (MDBK) and Rabbit
kidney 13 (RK-13) cells. All of these cells were cultivated with Eagle's
minimum essential medium (MEM) (Nissui, Tokyo, Japan) supple-
mented with 5–10% fetal bovine serum (FBS) and 100 U/ml penicillin
and 100 µg/ml streptomycin.
E. coli and plasmids
DH10β strain of E. coliwas used for construction andmaintenance of
BAC clones. The pZC320 plasmid (Shi and Biek, 1995) was used as the
basis of BAC vector, which was kindly provided by National Institute of
Genetics (Mishima, Japan). Other plasmids used were pUC19 (TAKARA,
Shiga, Japan) and pEGFP-N1 (Clontech, U.S.A.).
Construction of BAC plasmids
A fragment of the Ab4p genome corresponding nucleotide (nt) 812
to 4722 was ampliﬁed by PCR using the following primers: fORF1–5
5′-ACA GCG AAT TCA CAT TAG TTG CCA CGC TTC T-3′ and rORF1–5
5′-CAC TCG GAA TTC CCA CCT TCA TGT TCG TGA TG-3′ and was cloned
at pUC19 EcoRI site (pUC19-Ab4p). The Ab4p fragment contains
a single ClaI site (at nt 2838), which is located in the intergenic
region between ORF2 and ORF3. A ClaI-attL-attR-ClaI polynucleotide
(324 bp) was synthesized in Dragon Genomics Center (Mie, Japan).
This polynucleotide fragment was inserted at pUC19-Ab4p ClaI site
(pUC19-Ab4p-attLR). A pUC19-Ab4p-attB was constructed from
pUC19-Ab4p-attLR by removing the stuffed fragment with LR clonaseCX (M) Cells. The neuron cells were infected at a MOI of 1. At the indicated times after
ods. Intracellular (A) and extracellular (B) viruses were titrated by plaque formation on
268 S. Kasem et al. / Virology 400 (2010) 259–270reaction (Fig. 1A). LR clonase reaction was performed according to the
manufacturer's instructions of Gateway LR Clonase Enzyme Mix
(Invitrogen, Tokyo, Japan). The GFP expression cassette consisted of
human cytomegalovirus immediate early promoter, GFP gene and
an SV40 early mRNA polyadenylation signal in pEGFP-N1 was cloned
in BamHI–SphI sites of pZC320 multi cloning site (pZC320-GFP).
Additionally, an attP sequence was ampliﬁed from lambda phage DNA
(TAKARA BIO, Shiga, Japan) by PCR using the following primers: fattP
5′-AGCGAA TTC AAT GCT CTG TTA CAGGTC A-3′ and rattP 5′-TAC GCG
TCT CGA CGA AAT CAA ATA ATG ATT TTA TTT TGA CTG-3′. The attP
sequence fragment was cloned in EcoRI–SalI sites of pZC320-GFP
(pZC320-GFP-attP) (Fig. 1B). The pUC19-Ab4p-attB was linearized by
digestion with ScaI. The pZC320-GFP-attP was inserted into linearized
pUC19-Ab4p-attB by BP clonase reaction (pZC320-Ab4p) (Fig. 1C). BP
clonase reaction was performed according to the manufacturer's
instructions of Gateway BP Clonase Enzyme Mix (Invitrogen, Tokyo,
Japan).
Isolation of Ab4p BAC virus
RK-13 cells in a 24-well platewas infected by Ab4p at amultiplicity
of infection (MOI) of 0.1. After 60 min of adsorption, 1.0 µg of the linear
pZC320-GFP-Ab4p DNA per well was transfected into the RK-13 cells
by lipofectamine 2000 (Invitrogen, Tokyo, Japan) and incubated at
37 °C (Fig. 1D). After 5–7 days cultivation, supernatant was collected.
The supernatant was inoculated to MDBK cells. After 60 min of
adsorption, the MDBK cells were covered by MEM containing 1.5% of
carboxymethylcellulose and incubated for 4–5 days at 37 °C. Using
GFP ﬂuorescence as a marker, the desired virus (Ab4p BAC) identiﬁed
and selected under ﬂuorescent microscopy (Fig. 1E). The Ab4p BAC
virus was puriﬁed by three rounds of plaque puriﬁcation.
Transformation of E. coli and mutagenesis of pAb4p
Competent E. coli DH10β (Invitrogen, Tokyo, Japan) was used for
transformation. Circular viral DNA of Ab4p BAC was isolated from
infected FEK cells by the Hirt method (Hirt, 1967). Circular Ab4p BAC
DNA was electroporated into DH10β by using a Bio-Rad GenePulser
(Bio-Rad, Tokyo, Japan) with 0.1 cm cuvettes, 1.3 kV, 10 µF and 100 Ω.
The Ab4p BAC containing clones were selected by growth on LB
agar plates containing ampicillin at 50 µg/ml. Resistant bacterial
clones were isolated and grown overnight in LB medium containing
ampicillin. The presence of Ab4p BAC as a plasmid (pAb4p BAC) was
conﬁrmed by extraction of large plasmid DNA with Nucleo Bond BAC
100 kit (MACHEREY-NAGEL, USA) and restriction enzyme digestion
(NotI).
For modiﬁcation of pAb4p BAC, Red mutagenesis was used
(Datsenko andWanner, 2000; Thomson et al., 2003). Brieﬂy, competent
E. coli DH10β harboring pAb4p BAC and the Red/ET plasmid pKD46
[DH10β (pAb4p, pKD46)] were grown in Luria–Bertani broth (LB) with
tetracycline (30 µg/ml), ampicillin (50 µg/ml), and L-arabinose (0.1%
ﬁnal concentration) at 30 °C to an optical density at 600 nm of 0.6 and
thenmade electrocompetent exactly as previously described (Datsenko
andWanner, 2000). To delete ORF37 in pAb4pBAC,ORF37was replaced
with the rpsL-neo cassette (rpsL-neo gene) conferring streptomycin
sensitivity and kanamycin resistance, resulting in recombinant BAC
termed pAb4pΔORF37 BAC (Fig. 4) as follows. A pair of primer-1 (5′-
GGT CTT TAG CTT CGA TCT TAG TGT TTA TAC TTG CGT GTA GGC GCG
CCG ACG GCC TGG TGA TGA TGG CGG GAT CG-3′) and primer-2 (5′-CTC
CGT CGA GCT TCC CCG GAA GGT ACG CGA GCC GCC ATT GAT TTC TGA
AAT CAG AAG AAC TCG TCA AGA AGG CG-3′) containing 50-nucleotide
homology arms bordering the desired deletion from position 69043 to
69897 of gene 37 and 24 nucleotides (in boldface) for ampliﬁcation of
the rpsL-neo cassette sequences was designed to be used for
ampliﬁcation of the insertion fragment with the use of the rpsL-neo
template DNA (Gene Bridges) as a template DNA. The resulting 1420 bpPCR fragment was puriﬁed from agarose gel (QIAquick gel extraction
kit; QIAGEN) and electroporated intoDH10β (pAb4p, pKD46)using 0.1-
cm cuvettes (Bio-Rad Laboratories) under standard electroporation
conditions (1.35 kV/cm, 600Ω 10 µF). After electroporation, cells were
grown in 1 ml of LB for 70 min at 37 °C and plated onto LB agar plates
containing 50 µg/ml of ampicillin, 30 µg/ml tetracycline and 15 µg/ml
of kanamycin. Resistant colonies were picked into liquid LB medium,
grown at 37 °C, and small-scale preparations of mutant pAb4p-
DNA (pAb4pΔORF37 BAC) were obtained by alkaline lyses of E. coli
(Sambrook et al., 1989) to be conﬁrmed by PCR and to be digestedwith
various restriction enzymes.
Revertant virus construction
To replace the rpsL-neo gene with the ORF37 gene in the
pAb4pΔORF37 BAC, DH10β (pAb4pΔORF37, pKD46) were grown in
Luria–Bertani broth (LB) with tetracycline (30 µg/ml), ampicillin
(50 µg/ml), kanamycin (15 µg/ml) and L-arabinose (0.1% ﬁnal
concentration) at 30 °C to an optical density at 600 nm of 0.6 and
then made electrocompetent as previously described (Datsenko and
Wanner, 2000). ORF37 was ampliﬁed by PCR with a pair of primer-3
(5′-GGT CTT TAG CTT CGA TCT TAG TGT TTA TAC TTG CGT GTA GGC
GCG CCG AC-3′) and primer-4 (5′-CTC CGT CGA GCT TCC CCG GAA
GGT ACG CGA GCC GCC ATT GAT TTC TGA AA-3′) including 50-
nucleotide homology arms bordering the desired deletion from
position 69043 to 69897 of ORF37. The resulting 955 bp PCR fragment
was puriﬁed by agarose gel electrophoresis (QIAquick gel extraction
kit; QIAGEN) and electroporated into DH10β (pAb4pΔORF37, pKD46)
using 0.1 cm cuvettes (Bio-Rad Laboratories) under standard electro-
poration conditions (1.35 kV/cm, 600 Ω, 10 µF). After electroporation,
cells were grown in 1 ml of LB for 70 min at 37 °C and plated onto LB
agar plates containing 50 µg of ampicillin/ml, 50 µg of streptomycin.
Double resistant colonies were picked into liquid LB medium, grown
at 37 °C. Small-scale preparations of mutant DNA of pAb4pΔORF37R
BAC were obtained by alkaline lyses of E. coli (Sambrook et al., 1989),
conﬁrmed by PCR, digested with various restriction enzymes.
Regeneration of infectious Ab4p BAC, Ab4p attB, Ab4pΔORF37 and
Ab4pΔORF37R viruses
DNAwas extracted byusing aNucleoBondBAC100kit (MACHEREY-
NAGEL, USA) from each BAC culture. For Ab4p BAC, 1 µg of pAb4p BAC
DNAwas transfected into RK-13 cells in a 24-well plate by lipofectamine
2000 (Invitrogen) and incubated at 37 °C. Then, Ab4p BAC was isolated
as described above. For Ab4p attB, Ab4pΔORF37 and Ab4pΔORF37R,
the DNAs were constructed by LR clonase reaction, which excises the
BAC fragment from each BAC DNA. Then Ab4p attB, Ab4pΔORF37 and
Ab4pΔORF37R viruses were generated with the methods used for
regeneration of Ab4p BAC virus.
Virus growth kinetics and plaque area determinations
Titers of the viruses were determined by infecting MDBK cells at a
multiplicity of infection (MOI) of 0.1 for virus growth kinetics as
described by Pearson and Coen (2002). Conﬂuent monolayers of
MDBK cells in 24-well plates were infected with the Ab4p, Ab4p attB,
Ab4pΔORF37 and Ab4pΔORF37R. Supernatant and cells were then
collected at 0, 6, 12, 24, 36 and 48 h post infection each. A cell pellet
was resuspended in the same volume of MEM to be frozen–thawed
twice to release cell-associated virus. The titer of each sample was
assessed by plaque assay by of MDBK cells. Plaque areas were mea-
sured after plating of the viruses on MDBK cells and 3 days of incuba-
tion at 37 °C under a 0.6% methylcellulose overlay. For each virus,
plaque areas of at least 50 plaques for each experiment were
determined in triplicate using the ImageJ 1.28 software that is freely
available from the National Institutes of Mental Health webpage
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areas were statistically analyzed by an analysis of variance (ANOVA).
Virus growth kinetics in mouse neurons
To compare viral growth in the neurons, CX (M) cells (Sumitomo
Bakelite, Tokyo, Japan) derived from mouse cerebral cortexes were
cultured in 24-well plates coated with poly-L-lysine (Sumitomo
Bakelite) in neuron culture medium (Sumitomo Bakelite, Tokyo,
Japan). Titers of the various viruses were determined by infecting
CX (M) cells at 1 MOI. The supernatant and cells were separately
harvested at the indicated timing and virus titers were determined by
plaque assay on MDBK cells after freeze and thaw cycles as described
previously (Yamada et al., 2008).
Analysis of transcription kinetics by real-time RT-PCR
For analysis of transcription activity of ORF37, MDBK cells were
infected with Ab4p, Ab4p-attB, Ab4pΔORF37 and Ab4pΔORF37R,
resulting in 1 MOI. Total RNA was extracted by using Nucleospin RNA
kit (MACHEREY-NAGEL, USA) from the infected and uninfectedMDBK
cells harvested at 0, 2, 4, 6 and 8 h post infection. Then 1.5 µg of RNA
was heated at 95 °C for 5 min for denaturation, combinedwith reverse
transcriptase master mix consisting of 4 µl of 5×RT buffer (TOYOBO,
Osaka, Japan), 5 mM of dNTP (TAKARA), 25 pmol of random primer
(TOYOBO), 40 U of RNase inhibitor (TOYOBO) and 50 U of reverse
transcriptase (TOYOBO). The reaction mixture was incubated at 30 °C
for 10 min, 42 °C for 40 min followed by incubation at 99 °C for 5 min
to stop the reaction. A real-time PCR assay was carried out using
12.5 µl of SYBRPremix Ex Taq (TAKARA), 10 µMof speciﬁc primers and
10 ng of cDNA in the Thermal Cycler Dice Real Time System (TAKARA).
Primers sequences are for ORF37 (ORF37A 5′-CCG CAG CTG GAA ATA
AAC TC-3′ and ORF37B 5′-CCT GCA CCA TAT CAC GTT TG-3′), ORF36
(ORF36A 5′-CAC CTC CCT GTT GGC TAT GT-3′ and ORF36B 5′-TTC TCA
CGG AAG ACC AAA CC-3′), ORF38 (ORF38A 5′-ACT GGC GGA CTC TCT
TTG AA -3′ and ORF38B 5′-GTC TCC GAT GAG GTA GCG AG-3′), ORF33
(ORF33A 5′-TTG TTAGAG CCG TAC CCA CC-3′ and ORF33B 5′-AAA GTC
TCC ATC CTC AGC GA-3′) and ORF30 (DNA polymerase) primers
(ORF30A 5′-GTC AGGCCC ACAAAC TTGAT-3′ andORF30B 5′-ACT CGG
TTT ACG GAT TCA CG-3′). Relative quantities were measured by the
ΔΔCt method (Livak and Schmittgen, 2001).
Evaluation of growth activity by real-time PCR
The growth activities of the viruses and β-actin gene in MDBK
cells which were infected with Ab4p, Ab4p attB, Ab4pΔORF37 and
Ab4pΔORF37R, were evaluated by real-time PCR. Total DNA was
extracted from the infected and uninfected MDBK cells harvested at
0, 2, 4, 6 and 8 h post infection. The growth activities of all viruses
were evaluated through estimating a copy number of ORF30 (DNA
polymerase) DNA with β-actin gene control by real-time PCR as de-
scribed above.
Animal experiments
Animal experiments were conducted as described previously (Ho
and Mocarski, 1988; Osterrieder et al., 1996; Fukushi et al., 2000).
Brieﬂy, four-week-old speciﬁc pathogen free (SPF) male CBA/N1mice
(26 mice per each virus and control) were inoculated with a virus
preparation by the intranasal route at 1×105 pfu per head. Behavior
and body weight of eachmouse were observed from 3 days before the
inoculation to the end of the period. Body weights were evaluated by
analysis of variance and multiple comparisons of the groups. Two
mice from each group were euthanized every day from 1 to 10 dpi for
virus isolation and DNA detection. Lungs and the brain were used for
virological assay. All experiments were conducted under the guide-lines for animal experiments in Gifu University with certiﬁcation
by the committee of the Faculty of Applied Biological Sciences, Gifu
University.
Tissues were homogenized in MEM at 10% (w/v). The homo-
genates were centrifuged at 3000 rpm for 10 min to remove the
cellular debris. Supernatant was serially 10-fold diluted in MEM. A
volume of 0.1 ml per well was inoculated onto a conﬂuent MDBK
monolayer in 24-well plates. Virus titers were determined by plaque
assay. The detection limit in the organ homogenates was 1×102 pfu
per gram of a mouse organ. DNAwas extracted with a Sepagene kit for
virus DNA detection in mice organs (Sanko Junyaku, Japan). Viral DNA
was detected by using primers for ORF37 and primers for rpsL-neo
gene for the mutant virus. For histopathology, brains and lungs were
collected in buffered formalin and processed for histopathological
analysis (Fukushi et al., 2000; Leist et al., 1989).
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